Creating a diagnosis and treatment system for primary vitreoretinal lymphoma
Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma
Peking Union Medical College Hospital · NCT05950490
This study is trying to create a better way to diagnose and treat primary vitreoretinal lymphoma in newly diagnosed patients to improve their care and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT05950490 on ClinicalTrials.gov |
What this trial studies
This observational study aims to establish a comprehensive diagnosis and treatment system for primary vitreoretinal lymphoma (PVRL). It will create diagnostic criteria with high efficiency, develop standardized treatment pathways, and evaluate treatment efficacy and safety. Additionally, the study will identify prognosis evaluation indicators and explore the pathogenesis of PVRL, including specific tumor markers and therapeutic targets. The research will involve newly diagnosed PVRL patients at Peking Union Medical College Hospital.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed PVRL patients aged 18-75 who meet specific diagnostic criteria.
Not a fit: Patients with other tumors, uncontrolled infections, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment options for patients with primary vitreoretinal lymphoma.
How similar studies have performed: While there may be existing studies on lymphoma, this specific approach to PVRL is novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Newly diagnosed PVRL patients admitted to the Ophthalmology or Hematology departments of Peking Union Medical College Hospital from 2022 to 2024; * 18-75 years old; * The diagnosis was confirmed by pathology, aqueous humor/vitreous IL-10/IL-6, vitreous flow cytometry and gene rearrangement.; * HIV-Ab negative; * Creatinine clearance \> 50ml/min; * Sign informed consent. Exclusion Criteria: * Combined with other tumors; * Uncontrolled active infections; * Pregnant or lactating women; * Antitumor therapy other than the protocol of this study was used.
Where this trial is running
Beijing, Beijing
- Peking Union Medical College Hospital — Beijing, Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Yujing Qian
- Email: qianyujing777@126.com
- Phone: +86 15901597377
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Primary Vitreoretinal Lymphoma